Phillips Medisize targets formulation-device risk as inhaled therapies grow more complex
Inhalers are getting smarter, but complexity can backfire. Phillips Medisize is betting DPI success starts with patient-centric design.
Avalyn Pharma moves AP02 into Phase 2, exploring whether nebulized delivery can improve risk benefit balance in IPF
Avalyn Pharma advances inhaled AP02 into Phase 2 trials for IPF. Learn how lung targeted delivery could reshape antifibrotic treatment.
Aptar Pharma and COVIRIX Medical partner to develop inhaled broad-spectrum antiviral treatment
Aptar Pharma and COVIRIX Medical announce a DPI feasibility collaboration for inhaled broad-spectrum antivirals. Read the analysis.